Skip to main content

Table 6 Summary of randomized trials assessing the efficacy of letrozole

From: Hormonal, follicular and endometrial dynamics in letrozole-treated versus natural cycles in patients undergoing controlled ovarian stimulation

Study

(reference number)

Intervention

Cohort of patients

Conclusion

[20]

Letrozole (2.5 mg) Vs CC

Infertile women undergoing Superovulation and IUI.

Similar endometrial thickness and pregnancy rates.

[21]

letrozole Vs CC as adjuvants to rFSH 41 patients

Superovulation before IUI in unexplained infertility

Better endometrial thickness with letrozole. Similar pregnancy rate

[22]

Letrozole Vs CC 74 patients

Polycystic ovary syndrome

Similar endometrial thickness and pregnancy rate

[23]

Letrozole (2.5 mg) Vs CC

Polycystic ovary syndrome

Better endometrial thickness and pregnancy rate with letrozole.

[24]

Letrozole Vs CC

Polycystic ovary syndrome

No advantage to the use of letrozole over CC as a first-line treatment for induction of ovulation in women with PCOS

[25, 26]

Letrozole Vs CC

Superovulation before IUI in unexplained infertility

No superiority between letrozole and CC for inducing ovulation in women with unexplained infertility before IUI.

[27]

Letrozole Vs CC-gonadotropin

Superovulation before IUI in unexplained infertility

Letrozole is a good alternative to CC-gonadotropin.

[28]

Letrozole (2.5 mg) Vs CC 22 patients

superovulation in women with normal ovulation

CC is superior to 2.5 mg letrozole for superovulation induction in women with normal ovulation.

[29]

Letrozole (7.5 mg) Vs CC 46 patients

Polycystic ovary syndrome

Letrozole has better ovulation and PR in comparison to CC in patients with PCOS